Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

ABSTRACT:

Importance

To date, the benefit of genome-driven cancer therapy has not been quantified.

Objective

We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven therapy from 2006 to 2018.

Design, setting, and participants

Retrospective cross-sectional study using publically available data of (1) demographic characteristics of patients with advanced or metastatic cancer; (2) FDA data on cancer drugs approved from January 2006 through January 2018; (3) measures of response and duration of response from drug labels; and (4) published reports estimating the frequency of various genomic aberrations used to estimate what p

SUBMITTER: Marquart J 

PROVIDER: S-EPMC6143048 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature